Cell Source
New York
About Cell Source
Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company’s patented "Veto-Cell" technology represents a major breakthrough in immune system management - safe and selective “tolerizing” of immune response. Cell Source’s technology addresses one of the most fundamental challenges in human immunology: how to tune immune response so that it tolerates specific “desirable” foreign cells while continuing to attack all other potential threats. Cell Source is currently commercializing this groundbreaking innovation. Potential applications range from facilitating bone marrow and organ transplantation to effectively treating both blood cancers (e.g., Lymphoma) and non-malignant congenital diseases (e.g., Sickle Cell Anemia).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $11.0M
- Funding stage: IPO
- Last round: Post-IPO Debt (Jan 2026)
- Ticker: otcqb:CLCS
- Website: cell-source.com
- Phone: +97235621755
Industries & Categories
Biotechnology, Developer Platform, Medical
Canonical: https://fsome.com/organization/cell-source-114158 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.